RCUS Dividend History & Analysis | N/A Yield
RCUS has a dividend yield of N/A and paid N/A per share in the last 12M. Complete payout history, full analyses and peer comparison.
Top Dividend Payers in Biotechnology
| Symbol | Market Cap (USD) | Dividend Yield TTM | Yield on Cost (purchase 5y ago) |
|---|---|---|---|
| JBIO | 280 M | 20.9% | 0.31% |
| GILD | 155,333 M | 3.14% | 7.99% |
| ABBV | 410,546 M | 2.86% | 7.80% |
| AMGN | 180,930 M | 2.83% | 4.98% |
| HLN | 44,016 M | 1.83% | 2.46% |
| Symbol | Market Cap (USD) | Growth Rate (CAGR) | Payout Consistency |
|---|---|---|---|
| GRFS | 7,645 M | 127% | 60.7% |
| HLN | 44,016 M | 51.0% | 100% |
| AMGN | 180,930 M | 8.90% | 100% |
| ABBV | 410,546 M | 7.06% | 100% |
| GILD | 155,333 M | 3.16% | 100% |
Similar Stocks with Attractive Dividends - Compare RCUS Dividends with its Peer-Group
2.86% Yield
2.83% Yield
3.14% Yield
1.83% Yield
RCUS Dividend History: as of November 2025
No dividends paid yet.RCUS Dividend FAQ
Arcus Biosciences (NYSE:RCUS) is a clinical-stage biopharma focused on oncology immunotherapies in the United States. Its lead assets include Casdatifan (a HIF-2α inhibitor for renal cell carcinoma) and Domvanalimab (an anti-TIGIT antibody currently in Phase 2/3 trials for lung and gastrointestinal cancers). The pipeline also contains Quemliclustat (CD73 inhibitor in Phase 3 for lung cancer and Phase 1/1b for pancreatic cancer), Etrumadenant (dual A2a/A2b adenosine-receptor antagonist in Phase 2 for colorectal cancer), Zimberelimab (anti-PD-1), AB598 (CD39 antibody in Phase 1/1b for GI cancers) and AB801 (AXL inhibitor in Phase 1b for lung cancer). Arcus collaborates with AstraZeneca on the Phase 3 PACIFIC-8 trial (Domvanalimab + Durvalumab in Stage 3 NSCLC) and on a Phase 1/1b study of Casdatifan + Volrustomig in treatment-naïve clear-cell RCC, and partners with BVF Partners for inflammatory-disease programs.
What is the Dividend Yield of RCUS?
As of November 2025, RCUS`s dividend yield is %. This is calculated by dividing the trailing 12-month dividend rate (TTM rate) of - by the current share price of 21.23.Does RCUS pay a dividend?
As of November 2025 RCUS does not pay a dividend.How often does RCUS pay dividends?
Over the last 12 months, RCUS has issued dividend payments.Will RCUS pay dividends in 2025?
The next Ex-Dividend date for Arcus Biosciences (RCUS) is currently unknown.What is the next Ex-Dividend Date for RCUS?
The next Ex-Dividend date for Arcus Biosciences (RCUS) is currently unknown. We automatically update the next Ex-Dividend date when it is announced.What is the Dividend Growth of RCUS?
RCUS's average dividend growth rate over the past 5 years is -% per year.
What is the Yield on Cost of RCUS?
RCUS's 5-Year Yield on Cost is -%. If you bought RCUS's shares at 25.76 five years ago, your current annual dividend income (- per share, trailing 12 months) equals -% of your original purchase price.What is the Payout Consistency of RCUS?
RCUS Payout Consistency is 0.0%.
The payout consistency is a proprietary measure of how consistently a company has paid dividends over its lifetime and blends growth rate, number of dividend payments, interruptions or lowering dividends into one number.
Does RCUS have a good Dividend Yield?
RCUS`s % Dividend Yield is considered as unknown.What is the Dividend Payout Ratio of RCUS?
The Dividend Payout Ratio of RCUS is unknown.What is the Dividend Rating of RCUS?
RCUS`s Overall Dividend Rating is (unknown). Ratings surpassing 65% are regarded as acceptable, exceeding 75% are favorable and surpassing 85% are strong.Key Metric Definitions
- Dividend Yield: Annual dividend per share divided by current share price.
- Dividend Growth Rate: Compound annual growth rate of annual dividend per share over the last 5 years.
- Payout Ratio: Percentage of earnings paid as dividends (TTM).
- Payout Consistency: % of eligible periods with uninterrupted or increased dividends, measured over the entire lifetime of the stock or fund.
- Payout Frequency: Number of dividends paid in the last 12m (TTM).
- Overall Dividend Rating: Proprietary composite score, quantified on a scale from 0 to +100. Ratings surpassing 70 are regarded as favorable, while those exceeding 85 are strong.
- Total Return: Price appreciation plus dividends over specified period.
- Market Cap: Figures are in millions of the corresponding currency.
Last update: 2025-11-13 02:34